At the 2026 ASCO Annual Meeting, Zelgen Pharmaceuticals announced for the first time the Phase II clinical data of ZG005, a PD-1\/TIGIT bispecific antibody, in combination with bevacizumab as a first-line treatment for advanced hepatocellular carcinoma (HCC). Compared with the established standard regimen of sintilimab plus bevacizumab, the 20 mg\/kg and 10 mg\/kg dose groups of ZG005 showed a 65% and 59% reduction in the risk of disease progression or death, respectively. The objective response rates (ORR) reached 40.6% and 38.7%, respectively, both higher than the standard treatment group (ORR = 34.4%). The disease control rates (DCR) were 90.6% and 90.3%, respectively (control group: 75.0%).<\/p>\n\n\n\n
In fact, this is not the first time ZG005 has appeared on the international stage. As early as the 2025 ASCO Annual Meeting, Zelgen Pharmaceuticals had already disclosed the potential of ZG005 for the treatment of cervical cancer. In second-line or later cervical cancer patients who had not previously received immune checkpoint inhibitor therapy, the 20 mg\/kg group (N=22) achieved a confirmed ORR of 40.9%, with median progression-free survival (PFS) exceeding 11 months. In first-line cervical cancer patients, the 20 mg\/kg group (N=28) achieved an unconfirmed ORR as high as 82.1%, with a DCR of 96.4%.<\/p>\n\n\n\n
Buy TIGIT<\/strong> from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.<\/p>\n","protected":false},"excerpt":{"rendered":" At the 2026 ASCO Annual Meeting, Zelgen Pharmaceuticals announced for the first time the Phase II clinical data of ZG005, a PD-1\/TIGIT bispecific antibody, in combination with bevacizumab as a first-line treatment for advanced hepatocellular carcinoma (HCC). Compared with the established standard regimen of sintilimab plus bevacizumab, the 20 mg\/kg and 10 mg\/kg dose groups […]<\/p>\n","protected":false},"author":3,"featured_media":4217,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[16],"tags":[],"class_list":["post-4216","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"blocksy_meta":[],"yoast_head":"\n